{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:29:45Z","timestamp":1787041785145,"version":"build-2736575974"},"reference-count":186,"publisher":"American Chemical Society (ACS)","issue":"11","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["1R21CA228099-01A1"],"award-info":[{"award-number":["1R21CA228099-01A1"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008476","name":"University of California, Irvine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Gene therapy directly targets mutations causing disease, allowing for a specific treatment at a molecular level. Adeno-associated virus (AAV) has been of increasing interest as a gene delivery vehicle, as AAV vectors are safe, effective, and capable of eliciting a relatively contained immune response. With the recent FDA approval of two AAV drugs for treating rare genetic diseases, AAV vectors are now on the market and are being further explored for other therapies. While showing promise in immune privileged tissue, the use of AAV for systemic delivery is still limited due to the high prevalence of neutralizing antibodies (nAbs). To avoid nAb-mediated inactivation, engineered AAV vectors with modified protein capsids, materials tethered to the capsid surface, or fully encapsulated in a second, larger carrier have been explored. Many of these engineered AAVs have added benefits, including avoided immune response, overcoming the genome size limit, targeted and stimuli-responsive delivery, and multimodal therapy of two or more therapeutic modalities in one platform. Native and engineered AAV vectors have been tested to treat a broad range of diseases, including spinal muscular atrophy, retinal diseases, cancers, and tissue damage. This review will cover the benefits of AAV as a promising gene vector by itself, the progress and advantages of engineered AAV vectors, particularly synthetically engineered ones, and the current state of their clinical translation in therapy.<\/jats:p>","DOI":"10.1021\/acsnano.0c03850","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T14:19:57Z","timestamp":1603117197000},"page":"14262-14283","source":"Crossref","is-referenced-by-count":62,"title":["Synthetically\nEngineered Adeno-Associated Virus for\nEfficient, Safe, and Versatile Gene Therapy Applications"],"prefix":"10.1021","volume":"14","author":[{"given":"Margaret\nL.","family":"Lugin","sequence":"first","affiliation":[{"name":"University of California , , , ,","place":["Irvine, California, United States, 92697"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca T.","family":"Lee","sequence":"additional","affiliation":[{"name":"University of California , , , ,","place":["Irvine, California, United States, 92697"]},{"name":"University of California , , , ,","place":["Irvine, California, United States, 92697"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4086-6995","authenticated-orcid":true,"given":"Young Jik","family":"Kwon","sequence":"additional","affiliation":[{"name":"University of California , , , ,","place":["Irvine, California, United States, 92697"]},{"name":"University of California , , , ,","place":["Irvine, California, United States, 92697"]},{"name":"University of California , , , ,","place":["Irvine, California, United States, 92697"]},{"name":"University of California , , , ,","place":["Irvine, California, United States, 92697"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"2026081719275544500_cit1","doi-asserted-by":"publisher","first-page":"e3015","DOI":"10.1002\/jgm.3015","article-title":"Gene Therapy Clinical\nTrials Worldwide to 2017: An\nUpdate","volume":"20","author":"Ginn","year":"2018","journal-title":"J. Gene Med."},{"key":"2026081719275544500_cit2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.cossms.2012.10.002","article-title":"Synthetically Engineered Viruses: Can Synthetic Chemistry\nTame the Nature?","volume":"16","author":"Cho","year":"2012","journal-title":"Curr. Opin. Solid State Mater.\nSci."},{"key":"2026081719275544500_cit3","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1038\/ncomms7381","article-title":"3D Hotspots\nof Recurrent Retroviral Insertions Reveal Long-Range Interactions\nwith Cancer Genes","volume":"6","author":"Babaei","year":"2015","journal-title":"Nat. Commun."},{"key":"2026081719275544500_cit4","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1172\/JCI37630","article-title":"The Genotoxic Potential\nof Retroviral Vectors Is Strongly Modulated by Vector Design and Integration\nSite Selection in a Mouse Model of HSC Gene Therapy","volume":"119","author":"Montini","year":"2009","journal-title":"J. Clin. Invest."},{"key":"2026081719275544500_cit5","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/mt.2014.3","article-title":"Uncovering\nand Dissecting the Genotoxicity of Self-Inactivating Lentiviral Vectors in Vivo","volume":"22","author":"Cesana","year":"2014","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.nantod.2018.06.007","article-title":"Methodologies\nto Investigate Intracellular Barriers for Nucleic Acid Delivery in\nNon-Viral Gene Therapy","volume":"21","author":"Vermeulen","year":"2018","journal-title":"Nano Today"},{"key":"2026081719275544500_cit7","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1096\/fj.02-0127hyp","article-title":"Design of a Nonviral\nVector for Site-Selective, Efficient Integration into the Human Genome","volume":"16","author":"Kaminski","year":"2002","journal-title":"FASEB J."},{"key":"2026081719275544500_cit8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ccr.2018.07.001","article-title":"Non-Viral Gene Therapy Using Multifunctional Nanoparticles:\nStatus, Challenges, and Opportunities","volume":"374","author":"Lin","year":"2018","journal-title":"Coord.\nChem. Rev."},{"issue":"6372","key":"2026081719275544500_cit9","doi-asserted-by":"publisher","first-page":"eaan4672","DOI":"10.1126\/science.aan4672","article-title":"Gene Therapy Comes of Age","volume":"359","author":"Dunbar","year":"2018","journal-title":"Science"},{"key":"2026081719275544500_cit10","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12015-018-9866-1","article-title":"Biological Products:\nCellular Therapy and FDA Approved\nProducts","volume":"15","author":"Golchin","year":"2019","journal-title":"Stem Cell Reviews and Reports."},{"key":"2026081719275544500_cit11","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1038\/d41573-019-00121-9","article-title":"FDA New Drug\nApprovals in Q2 2019","volume":"18","author":"Urquhart","year":"2019","journal-title":"Nat. Rev. Drug Discovery"},{"key":"2026081719275544500_cit12","first-page":"1","article-title":"Adeno-Associated\nVirus Biology","volume-title":"Adeno-Associated Virus:\nMethods and Protocols","author":"Weitzman","year":"2011"},{"key":"2026081719275544500_cit13","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1073\/pnas.87.6.2211","article-title":"Site-Specific Integration by Adeno-Associated Virus","volume":"87","author":"Kotin","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026081719275544500_cit14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-Associated\nDefective Virus\nParticles","volume":"149","author":"Atchison","year":"1965","journal-title":"Science"},{"key":"2026081719275544500_cit15","doi-asserted-by":"crossref","first-page":"6603","DOI":"10.1016\/S0021-9258(18)50411-7","article-title":"Adeno-Associated\nVirus DNA Replication Complexes in\nHerpes Simplex Virus or Adenovirus-Infected Cells","volume":"254","author":"Handa","year":"1979","journal-title":"J. Biol. Chem."},{"key":"2026081719275544500_cit16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1073\/pnas.56.1.86","article-title":"Nucleic Acid from an Adeno-Associated\nVirus: Chemical and Physical Studies","volume":"56","author":"Rose","year":"1966","journal-title":"Proc.\nNatl. Acad. Sci. U. S. A."},{"key":"2026081719275544500_cit17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1073\/pnas.55.6.1467","article-title":"Studies of Small DNA Viruses Found\nin Various Adenovirus Preparations: Physical, Biological, and Immunological\nCharacteristics","volume":"55","author":"Hoggan","year":"1966","journal-title":"Proc. Natl. Acad. Sci. U. S.\nA."},{"key":"2026081719275544500_cit18","doi-asserted-by":"publisher","first-page":"6466","DOI":"10.1073\/pnas.81.20.6466","article-title":"Use of Adeno-Associated\nVirus as a Mammalian DNA Cloning\nVector: Transduction of Neomycin Resistance into Mammalian Tissue\nCulture Cells","volume":"81","author":"Hermonat","year":"1984","journal-title":"Proc. Natl. Acad. Sci. U. S.\nA."},{"key":"2026081719275544500_cit19","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1073\/pnas.79.6.2077","article-title":"Cloning of Adeno-Associated\nVirus into PBR322: Rescue of Intact Virus from the\nRecombinant Plasmid in Human Cells","volume":"79","author":"Samulski","year":"1982","journal-title":"Proc. Natl.\nAcad. Sci. U. S. A."},{"key":"2026081719275544500_cit20","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/0092-8674(83)90342-2","article-title":"Rescue of Adeno-Associated\nVirus from Recombinant Plasmids: Gene Correction within the Terminal\nRepeats of AAV","volume":"33","author":"Samulski","year":"1983","journal-title":"Cell"},{"key":"2026081719275544500_cit21","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1128\/JVI.63.9.3822-3828.1989","article-title":"Helper-Free\nStocks of Recombinant\nAdeno-Associated Viruses: Normal Integration Does Not Require Viral\nGene Expression","volume":"63","author":"Samulski","year":"1989","journal-title":"J. Virol."},{"key":"2026081719275544500_cit22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-642-80207-2_1","article-title":"Biology of Adeno-Associated\nVirus","volume-title":"Adeno-Associated Virus (AAV) Vectors\nin Gene Therapy","author":"Berns","year":"1996"},{"key":"2026081719275544500_cit23","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1128\/JVI.79.4.2528-2540.2005","article-title":"Mutational Analysis of Narrow Pores\nat the Fivefold Symmetry Axes of Adeno-Associated Virus Type 2 Capsids\nReveals a Dual Role in Genome Packaging and Activation of Phospholipase\nA2 Activity","volume":"79","author":"Bleker","year":"2005","journal-title":"J. Virol."},{"key":"2026081719275544500_cit24","first-page":"47","article-title":"AAV\nCapsid Structure and Cell Interactions","volume-title":"Adeno-Associated Virus: Methods and Protocols","author":"Agbandje-McKenna","year":"2011"},{"key":"2026081719275544500_cit25","doi-asserted-by":"publisher","first-page":"6344","DOI":"10.1128\/JVI.78.12.6344-6359.2004","article-title":"Circulating\nAnti-Wild-Type\nAdeno-Associated Virus Type 2 (AAV2) Antibodies Inhibit Recombinant\nAAV2 (RAAV2)-Mediated, but Not RAAV5-Mediated, Gene Transfer in the\nBrain","volume":"78","author":"Peden","year":"2004","journal-title":"J. Virol."},{"key":"2026081719275544500_cit26","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","article-title":"Analysis\nof AAV Serotypes 1\u20139 Mediated Gene Expression and Tropism in\nMice after Systemic Injection","volume":"16","author":"Zincarelli","year":"2008","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit27","first-page":"93","article-title":"Exploiting Natural\nDiversity of AAV\nfor the Design of Vectors with Novel Properties","volume-title":"Adeno-Associated Virus: Methods and Protocols","author":"Gao","year":"2011"},{"key":"2026081719275544500_cit28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-Associated Virus Serotypes:\nVector Toolkit for Human Gene Therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol.\nTher."},{"key":"2026081719275544500_cit29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/gt.2008.170","article-title":"Tailoring the AAV Vector Capsid for\nGene Therapy","volume":"16","author":"Vandenberghe","year":"2009","journal-title":"Gene Ther."},{"key":"2026081719275544500_cit30","doi-asserted-by":"publisher","first-page":"100604","DOI":"10.1016\/j.ymgmr.2020.100604","article-title":"Intravenous\nDelivery for Treatment of Mucopolysaccharidosis Type I: A Comparison\nof AAV Serotypes 9 and Rh10","volume":"24","author":"Belur","year":"2020","journal-title":"Mol. Genet. Metab.\nRep."},{"key":"2026081719275544500_cit31","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fnmol.2015.00036","article-title":"Systemic AAVrh10\nProvides Higher\nTransgene Expression than AAV9 in the Brain and the Spinal Cord of\nNeonatal Mice","volume":"8","author":"Tanguy","year":"2015","journal-title":"Front. Mol. Neurosci."},{"key":"2026081719275544500_cit32","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.4049\/jimmunol.0803965","article-title":"Adeno-Associated Virus Capsid Structure\nDrives CD4-Dependent CD8+ T Cell Response to Vector Encoded Proteins","volume":"182","author":"Mays","year":"2009","journal-title":"J. Immunol."},{"key":"2026081719275544500_cit33","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/mt.2011.287","article-title":"The AAV Vector Toolkit:\nPoised at\nthe Clinical Crossroads","volume":"20","author":"Asokan","year":"2012","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit34","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1128\/JVI.00649-08","article-title":"Adeno-Associated\nVirus Vector Genomes Persist as Episomal Chromatin in Primate Muscle","volume":"82","author":"Penaud-Budloo","year":"2008","journal-title":"J. Virol."},{"key":"2026081719275544500_cit35","unstructured":"ClinicalTrials.gov;\nU.S. National Library of Medicine. https:\/\/clinicaltrials.gov\/ct2\/results?cond=&term=aav&cntry=&state=&city=&dist= (accessed 2020-02-24)."},{"key":"2026081719275544500_cit36","unstructured":"Glybera. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/glybera (accessed\n2020-03-09)."},{"key":"2026081719275544500_cit37","unstructured":"Gaudet, D.\n          \n          Efficacy and Safety\nof Human Lipoprotein Lipase (LPL)\u00ad[S447X] Expressed by an Adeno-Associated\nViral Vector in LPL-Deficient Subjects. Clinical\nTrial Identifier NCT00891306; NIH U.S. National\nLibrary of Medicine: Bethesda, MD, 2011. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00891306?term=NCT00891306&draw=2 (accessed 2020-03-09)."},{"key":"2026081719275544500_cit38","unstructured":"LUXTURNA; U.S. Food & Drug Administration: Silver Springs, MD, 2018. https:\/\/www.fda.gov\/vaccines-blood-biologics\/cellular-gene-therapy-products\/luxturna (accessed 2020-03-05)."},{"key":"2026081719275544500_cit39","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and Safety of Voretigene Neparvovec\n(AAV2-HRPE65v2) in Patients\nwith RPE65-Mediated Inherited Retinal Dystrophy: A Randomised, Controlled,\nOpen-Label, Phase 3 Trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"2026081719275544500_cit40","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1167\/iovs.15-18167","article-title":"Omics in Ophthalmology: Advances in Genomics and Precision\nMedicine for Leber Congenital Amaurosis and Age-Related Macular Degeneration","volume":"57","author":"den\nHollander","year":"2016","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081719275544500_cit41","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/ejhg.2015.241","article-title":"Comprehensive Genotyping Reveals RPE65 as the Most\nFrequently Mutated Gene in Leber Congenital Amaurosis in Denmark","volume":"24","author":"Astuti","year":"2016","journal-title":"Eur. J. Hum. Genet."},{"key":"2026081719275544500_cit42","doi-asserted-by":"publisher","first-page":"3088","DOI":"10.1073\/pnas.95.6.3088","article-title":"Mutations in the RPE65 Gene in Patients with Autosomal\nRecessive Retinitis Pigmentosa or Leber Congenital Amaurosis","volume":"95","author":"Morimura","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026081719275544500_cit43","first-page":"4293","article-title":"Genetics and Phenotypes\nof RPE65 Mutations in Inherited Retinal Degeneration","volume":"41","author":"Thompson","year":"2000","journal-title":"Invest. Ophthalmol. Visual Sci."},{"key":"2026081719275544500_cit44","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/3813","article-title":"Rpe65 Is Necessary\nfor Production of 11-Cis-Vitamin A in the Retinal Visual Cycle","volume":"20","author":"Redmond","year":"1998","journal-title":"Nat. Genet."},{"key":"2026081719275544500_cit45","doi-asserted-by":"publisher","first-page":"13658","DOI":"10.1073\/pnas.0504167102","article-title":"Mutation of Key Residues of RPE65 Abolishes Its Enzymatic\nRole as Isomerohydrolase in the Visual Cycle","volume":"102","author":"Redmond","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026081719275544500_cit46","unstructured":"Zolgensma; U.S. Food &\nDrug Administration: Silver Springs,\nMD, 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/zolgensma (accessed\n2020-03-05)."},{"key":"2026081719275544500_cit47","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/0092-8674(95)90460-3","article-title":"Identification and\nCharacterization of a Spinal Muscular Atrophy-Determining Gene","volume":"80","author":"Lefebvre","year":"1995","journal-title":"Cell"},{"key":"2026081719275544500_cit48","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/nrn2670","article-title":"Spinal Muscular Atrophy: Why Do Low Levels of Survival\nMotor Neuron Protein Make Motor Neurons Sick?","volume":"10","author":"Burghes","year":"2009","journal-title":"Nat. Rev. Neurosci."},{"key":"2026081719275544500_cit49","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/0960-8966(94)90090-6","article-title":"The Natural History of Type I (Severe) Spinal Muscular\nAtrophy","volume":"4","author":"Thomas","year":"1994","journal-title":"Neuromuscular Disord."},{"key":"2026081719275544500_cit50","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","article-title":"Spinal Muscular\nAtrophy: A Timely Review","volume":"68","author":"Kolb","year":"2011","journal-title":"Arch. Neurol."},{"key":"2026081719275544500_cit51","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4&lt;288::AID-AJH4&gt;3.0.CO;2-I","article-title":"Hemophilia\nSurveillance System Project\nInvestigators. Occurrence of Hemophilia in the United States","volume":"59","author":"Soucie","year":"1998","journal-title":"Am. J. Hematol."},{"key":"2026081719275544500_cit52","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the Management\nof Hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"2026081719275544500_cit53","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1056\/NEJMoa067659","article-title":"Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys\nwith Severe Hemophilia","volume":"357","author":"Manco-Johnson","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"2026081719275544500_cit54","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12959-016-0103-3","article-title":"Aspects of\nProphylactic Treatment of Hemophilia","volume":"14","author":"Ljung","year":"2016","journal-title":"Thromb.\nJ."},{"key":"2026081719275544500_cit55","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2450\/2012.0147-11","article-title":"Prophylaxis\nin Haemophilia Should Be Life-Long","volume":"10","author":"Makris","year":"2012","journal-title":"Blood Transfusion."},{"key":"2026081719275544500_cit56","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal Treatment\nStrategies for Hemophilia: Achievements and Limitations of Current\nProphylactic Regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"key":"2026081719275544500_cit57","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1002\/pbc.24340","article-title":"Hemophilia\nand Prophylaxis","volume":"60","author":"Ljung","year":"2013","journal-title":"Pediatric Blood & Cancer."},{"key":"2026081719275544500_cit58","unstructured":"Study to Evaluate the Efficacy and Safety\nof Valoctocogene Roxaparvovec,\nwith Prophylactic Steroids in Hemophilia A (GENEr8-3). Clinical Trial Identifier NCT04323098; NIH U.S. National Library of Medicine: Bethesda, MD, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04323098 (accessed 2020-07-21)."},{"key":"2026081719275544500_cit59","unstructured":"Study to Evaluate\nthe Efficacy and Safety of PF-07055480 in Moderately\nSevere to Severe Hemophilia A Adults (AFFINE). Clinical Trail NCT04370054; NIH U.S. National\nLibrary of Medicine: Bethesda, MD, 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04370054 (accessed 2020-07-21)."},{"key":"2026081719275544500_cit60","unstructured":"George, L.\n          \n          Dose-Finding Study\nof SPK-8016 Gene Therapy in Patients with Hemophilia A to Support\nEvaluation in Individuals with FVIII Inhibitors. Clinical Trial Identifier NCT03734588; NIH\nU.S. National Library of Medicine: Bethesda, MD, 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03734588 (accessed 2020-07-21)."},{"key":"2026081719275544500_cit61","unstructured":"Gene Therapy Study\nin Severe Haemophilia A Patients. Clinical\nTrial Identifier NCT02576795; NIH U.S. National\nLibrary of Medicine: Bethesda, MD, 2015. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02576795 (accessed 2020-07-21)."},{"key":"2026081719275544500_cit62","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.ymthe.2017.12.009","article-title":"Gene Therapy with BMN 270 Results\nin Therapeutic Levels of FVIII in Mice and Primates and Normalization\nof Bleeding in Hemophilic Mice","volume":"26","author":"Bunting","year":"2018","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit63","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3389\/fimmu.2020.00618","article-title":"Translational Potential\nof Immune Tolerance Induction\nby AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A","volume":"11","author":"Samelson-Jones","year":"2020","journal-title":"Front. Immunol."},{"key":"2026081719275544500_cit64","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa1908490","article-title":"Multiyear Follow-up of AAV5-HFVIII-SQ\nGene Therapy for Hemophilia A","volume":"382","author":"Pasi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"2026081719275544500_cit65","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update\non Clinical Gene Therapy for\nHemophilia","volume":"133","author":"Perrin","year":"2019","journal-title":"Blood"},{"key":"2026081719275544500_cit66","unstructured":"Gene Therapy Study in Severe Hemophilia\nA Patients with Antibodies\nagainst AAV5 (270-203). Clinical Trial Identifier\n NCT03520712; NIH U.S. National Library of\nMedicine: Bethesda, MD, 2018. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03520712 (accessed 2020-07-21)."},{"key":"2026081719275544500_cit67","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/nature01661","article-title":"Evolving\nConcepts of Rheumatoid Arthritis","volume":"423","author":"Firestein","year":"2003","journal-title":"Nature"},{"key":"2026081719275544500_cit68","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00296-017-3726-1","article-title":"Prevalence of Rheumatoid\nArthritis\nin the United States Adult Population in Healthcare Claims Databases,\n2004\u20132014","volume":"37","author":"Hunter","year":"2017","journal-title":"Rheumatol. Int."},{"key":"2026081719275544500_cit69","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1517\/13543776.18.7.723","article-title":"The Development of\nNovel Therapies for Rheumatoid Arthritis","volume":"18","author":"Quan","year":"2008","journal-title":"Expert\nOpin. Ther. Pat."},{"key":"2026081719275544500_cit70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College\nof Rheumatology Guideline for\nthe Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis\nRheumatol."},{"key":"2026081719275544500_cit71","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1478-6354-13-S1-S5","article-title":"Advances in Rheumatology:\nNew Targeted Therapeutics","volume":"13","author":"Tak","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"2026081719275544500_cit72","unstructured":"Burggraaf, K.\n          \n          Arthrogen. A Single\nDose Clinical Trial to Study the Safety of ART-I02 in Patients with\nArthritis. Clinical Trial Identifier NCT02727764; NIH U.S. National Library of Medicine: Bethesda, MD, 2016. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02727764 (accessed 2020-07-21)."},{"key":"2026081719275544500_cit73","doi-asserted-by":"publisher","first-page":"3242","DOI":"10.2741\/1475","article-title":"IFN-Beta\nin Rheumatoid Arthritis","volume":"9","author":"Tak","year":"2004","journal-title":"Front. Biosci., Landmark\nEd."},{"key":"2026081719275544500_cit74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0130612","article-title":"Preclinical\nPotency and Biodistribution Studies of an AAV 5 Vector Expressing\nHuman Interferon-\u03b2 (ART-I02) for Local Treatment of Patients\nwith Rheumatoid Arthritis","volume":"10","author":"Aalbers","year":"2015","journal-title":"PLoS One"},{"key":"2026081719275544500_cit75","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1136\/ard.2004.035063","article-title":"Enhanced Gene Transfer\nto Arthritic Joints Using Adeno-Associated Virus Type 5: Implications\nfor Intra-Articular Gene Therapy","volume":"64","author":"Adriaansen","year":"2005","journal-title":"Ann. Rheum.\nDis."},{"key":"2026081719275544500_cit76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4939-9139-6_1","article-title":"Design of AAV\nVectors for Delivery of RNAi","volume-title":"Adeno-Associated\nVirus Vectors","author":"Borel","year":"2019"},{"key":"2026081719275544500_cit77","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.ymthe.2019.11.018","article-title":"Effective\nand Accurate Gene Silencing\nby a Recombinant AAV-Compatible MicroRNA Scaffold","volume":"28","author":"Xie","year":"2020","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit78","unstructured":"Safety and Proof-of-Concept (POC) Study with AMT-130\nin Adults with\nEarly Manifest Huntington Disease. Identifier\nNCT04120493; NIH U.S. National Library of\nMedicine: Bethesda, MD, 2019. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04120493 (accessed 2020-03-05)."},{"key":"2026081719275544500_cit79","doi-asserted-by":"publisher","first-page":"15005","DOI":"10.1038\/nrdp.2015.5","article-title":"Huntington Disease","volume":"1","author":"Bates","year":"2015","journal-title":"Nat. Rev.\nDis. Primers"},{"issue":"1","key":"2026081719275544500_cit80","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13311-013-0244-z","article-title":"Treatment\nof Huntington\u2019s Disease","volume":"11","author":"Frank","year":"2014","journal-title":"Neurotherapeutics"},{"key":"2026081719275544500_cit81","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.ymthe.2018.02.002","article-title":"Translation of MicroRNA-Based Huntingtin-Lowering\nTherapies from Preclinical Studies to the Clinic","volume":"26","author":"Miniarikova","year":"2018","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit82","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.omtm.2019.09.010","article-title":"AAV5-MiHTT Lowers Huntingtin MRNA and Protein without\nOff-Target Effects in Patient-Derived Neuronal Cultures and Astrocytes","volume":"15","author":"Keskin","year":"2019","journal-title":"Mol. Ther.--Methods Clin. Dev."},{"key":"2026081719275544500_cit83","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.ymthe.2018.06.021","article-title":"AAV5-MiHTT\nGene Therapy Demonstrates Broad Distribution and Strong Human Mutant\nHuntingtin Lowering in a Huntington\u2019s Disease Minipig Model","volume":"26","author":"Evers","year":"2018","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit84","doi-asserted-by":"publisher","first-page":"9281","DOI":"10.1128\/JVI.74.19.9281-9293.2000","article-title":"Monoclonal\nAntibodies against the\nAdeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and\nIdentification of Capsid Domains Involved in AAV-2\u2013Cell Interaction\nand Neutralization of AAV-2 Infection","volume":"74","author":"Wobus","year":"2000","journal-title":"J. Virol."},{"key":"2026081719275544500_cit85","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1089\/hum.2011.031","article-title":"Impact of Pre-Existing\nImmunity on\nGene Transfer to Nonhuman Primate Liver with Adeno-Associated Virus\n8 Vectors","volume":"22","author":"Wang","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"2026081719275544500_cit86","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of Serum IgG and Neutralizing\nFactors against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8,\nand 9 in the Healthy Population: Implications for Gene Therapy Using\nAAV Vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"2026081719275544500_cit87","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects\nof Transient\nImmunosuppression on Adeno-Associated, Virus-Mediated, Liver-Directed\nGene Transfer in Rhesus Macaques and Implications for Human Gene Therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"2026081719275544500_cit88","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human Immunoglobulin\nInhibits Liver Transduction by AAV Vectors at Low AAV2 Neutralizing\nTiters in SCID Mice","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood"},{"key":"2026081719275544500_cit89","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-Associated\nVirus Antibody Profiles in Newborns, Children, and Adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin. Vaccine Immunol."},{"key":"2026081719275544500_cit90","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/jmv.21360","article-title":"Diverse IgG Subclass Responses to Adeno-Associated\nVirus Infection and Vector Administration","volume":"81","author":"Murphy","year":"2009","journal-title":"J.\nMed. Virol."},{"key":"2026081719275544500_cit91","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1086\/595830","article-title":"Worldwide\nEpidemiology of Neutralizing Antibodies to Adeno-Associated Viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J. Infect. Dis."},{"key":"2026081719275544500_cit92","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1099\/vir.0.035113-0","article-title":"Examining the Cross-Reactivity and Neutralization Mechanisms\nof a Panel of MAbs against Adeno-Associated Virus Serotypes 1 and\n5","volume":"93","author":"Harbison","year":"2012","journal-title":"J. Gen. Virol."},{"key":"2026081719275544500_cit93","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1128\/JVI.02710-14","article-title":"Adeno-Associated Virus Serotype 1\n(AAV1)-and AAV5-Antibody Complex Structures Reveal Evolutionary Commonalities\nin Parvovirus Antigenic Reactivity","volume":"89","author":"Tseng","year":"2015","journal-title":"J. Virol."},{"key":"2026081719275544500_cit94","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1128\/JVI.74.4.1761-1766.2000","article-title":"Epitope\nMapping of Human Anti-Adeno-Associated\nVirus Type 2 Neutralizing Antibodies: Implications for Gene Therapy\nand Virus Structure","volume":"74","author":"Moskalenko","year":"2000","journal-title":"J. Virol."},{"key":"2026081719275544500_cit95","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3389\/fimmu.2013.00261","article-title":"Immunology of AAV-Mediated\nGene Transfer in the Eye","volume":"4","author":"Willett","year":"2013","journal-title":"Front. Immunol."},{"key":"2026081719275544500_cit96","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 Gene Therapy\nfor Duchenne Muscular Dystrophy Using a Translational Optimized AAV\nVector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit97","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jconrel.2017.08.005","article-title":"Application\nof Polyploid Adeno-Associated Virus Vectors for Transduction Enhancement\nand Neutralizing Antibody Evasion","volume":"262","author":"Chai","year":"2017","journal-title":"J. Controlled\nRelease"},{"key":"2026081719275544500_cit98","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.imlet.2016.06.004","article-title":"Transduction of Interleukin-10\nthrough Renal Artery Attenuates Vascular Neointimal Proliferation\nand Infiltration of Immune Cells in Rat Renal Allograft","volume":"176","author":"Xie","year":"2016","journal-title":"Immunol. Lett."},{"key":"2026081719275544500_cit99","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1002\/jgm.1161","article-title":"Coating\nof Adeno-Associated Virus with Reactive Polymers Can Ablate Virus\nTropism, Enable Retargeting and Provide Resistance to Neutralising\nAntisera","volume":"10","author":"Carlisle","year":"2008","journal-title":"J. Gene Med."},{"key":"2026081719275544500_cit100","doi-asserted-by":"publisher","first-page":"12900","DOI":"10.1128\/JVI.76.24.12900-12907.2002","article-title":"Conjugate-Based Targeting of Recombinant\nAdeno-Associated\nVirus Type 2 Vectors by Using Avidin-Linked Ligands","volume":"76","author":"Ponnazhagan","year":"2002","journal-title":"J. Virol."},{"key":"2026081719275544500_cit101","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/smll.201201661","article-title":"Site-Specific\nModification of Adeno-Associated\nViruses via a Genetically Engineered Aldehyde Tag","volume":"9","author":"Liu","year":"2013","journal-title":"Small"},{"key":"2026081719275544500_cit102","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.ijpharm.2011.10.019","article-title":"Heparin-Coated Superparamagnetic\nNanoparticle-Mediated Adeno-Associated Virus Delivery for Enhancing\nCellular Transduction","volume":"421","author":"Hwang","year":"2011","journal-title":"Int. J. Pharm."},{"key":"2026081719275544500_cit103","doi-asserted-by":"publisher","first-page":"8654","DOI":"10.1016\/j.biomaterials.2011.07.075","article-title":"Magnetically\nEnhanced Adeno-Associated Viral Vector Delivery for Human Neural Stem\nCell Infection","volume":"32","author":"Kim","year":"2011","journal-title":"Biomaterials"},{"key":"2026081719275544500_cit104","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.2147\/IJN.S26891","article-title":"A Novel Polyethyleneimine-Coated\nAdenoassociated Virus-Like Particle Formulation for Efficient SiRNA\nDelivery in Breast Cancer Therapy: Preparation and in Vitro Analysis","volume":"7","author":"Shao","year":"2012","journal-title":"Int. J. Nanomed."},{"key":"2026081719275544500_cit105","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1002\/jgm.779","article-title":"Effect of Polyethylenimine\non Recombinant\nAdeno-Associated Virus Midiated Insulin Gene Therapy","volume":"7","author":"Hsu","year":"2005","journal-title":"J. Gene Med."},{"key":"2026081719275544500_cit106","doi-asserted-by":"publisher","first-page":"9239","DOI":"10.1016\/j.biomaterials.2012.09.018","article-title":"Controlled Delivery of Recombinant\nAdeno-Associated Virus Serotype 2 Using PH-Sensitive Polyethylene\nGlycol-Poly-L-Histidine Hydrogels","volume":"33","author":"Zeng","year":"2012","journal-title":"Biomaterials"},{"key":"2026081719275544500_cit107","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1016\/j.actbio.2011.06.035","article-title":"Electrospun Nanofibrous\nScaffolds for Controlled Release\nof Adeno-Associated Viral Vectors","volume":"7","author":"Lee","year":"2011","journal-title":"Acta Biomater."},{"key":"2026081719275544500_cit108","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00441-011-1197-3","article-title":"Synthetic\nScaffold Coating with Adeno-Associated Virus Encoding BMP2 to Promote\nEndogenous Bone Repair","volume":"347","author":"Dupont","year":"2012","journal-title":"Cell Tissue Res."},{"key":"2026081719275544500_cit109","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.biomaterials.2017.04.015","article-title":"Sustained Viral Gene Delivery from\na Micro-Fibrous, Elastomeric Cardiac Patch to the Ischemic Rat Heart","volume":"133","author":"Gu","year":"2017","journal-title":"Biomaterials"},{"key":"2026081719275544500_cit110","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.actbio.2015.02.013","article-title":"Effective and Durable Genetic Modification\nof Human Mesenchymal Stem Cells via Controlled Release\nof RAAV Vectors from Self-Assembling Peptide Hydrogels with a Maintained\nDifferentiation Potency","volume":"18","author":"Rey-Rico","year":"2015","journal-title":"Acta Biomater."},{"key":"2026081719275544500_cit111","doi-asserted-by":"publisher","first-page":"1800427","DOI":"10.1002\/adom.201800427","article-title":"Ultrasoft and Highly\nStretchable\nHydrogel Optical Fibers for in Vivo Optogenetic Modulations","volume":"6","author":"Wang","year":"2018","journal-title":"Adv. Opt. Mater."},{"key":"2026081719275544500_cit112","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1111\/j.1349-7006.1998.tb00570.x","article-title":"Improvement of Transduction Efficiency\nof Recombinant Adeno-Associated Virus Vector by Entrapment in Multilamellar\nLiposomes","volume":"89","author":"Mizuno","year":"1998","journal-title":"Jpn. J. Cancer Res."},{"key":"2026081719275544500_cit113","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1038\/mt.2011.303","article-title":"Microvesicle-Associated AAV Vector\nas a Novel Gene Delivery System","volume":"20","author":"Maguire","year":"2012","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit114","doi-asserted-by":"publisher","first-page":"7598","DOI":"10.1016\/j.biomaterials.2014.05.032","article-title":"Naturally Enveloped\nAAV Vectors for\nShielding Neutralizing Antibodies and Robust Gene Delivery in Vivo","volume":"35","author":"Gyo\u0308rgy","year":"2014","journal-title":"Biomaterials"},{"key":"2026081719275544500_cit115","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/gt.2016.11","article-title":"Exosome-Associated\nAAV Vector as a Robust and Convenient Neuroscience Tool","volume":"23","author":"Hudry","year":"2016","journal-title":"Gene Ther."},{"key":"2026081719275544500_cit116","doi-asserted-by":"publisher","first-page":"8705","DOI":"10.1021\/acsnano.6b04155","article-title":"Viral\/Nonviral\nChimeric Nanoparticles to Synergistically\nSuppress Leukemia Proliferation via Simultaneous\nGene Transduction and Silencing","volume":"10","author":"Hong","year":"2016","journal-title":"ACS Nano"},{"key":"2026081719275544500_cit117","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/mt.2012.186","article-title":"Displaying High-Affinity Ligands on Adeno-Associated\nViral Vectors Enables Tumor Cell-Specific and Safe Gene Transfer","volume":"21","author":"Mu\u0308nch","year":"2013","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit118","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2014.08.020","article-title":"Enhanced Gene Delivery in Porcine\nVasculature Tissue Following Incorporation of Adeno-Associated Virus\nNanoparticles into Porous Silicon Microparticles","volume":"194","author":"McConnell","year":"2014","journal-title":"J. Controlled Release"},{"key":"2026081719275544500_cit119","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1021\/acsnano.5b05558","article-title":"Light-Activated Nuclear Translocation of Adeno-Associated Virus Nanoparticles\nUsing Phytochrome B for Enhanced, Tunable, and Spatially Programmable\nGene Delivery","volume":"10","author":"Gomez","year":"2016","journal-title":"ACS Nano"},{"key":"2026081719275544500_cit120","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1021\/acsbiomaterials.6b00439","article-title":"Role of Tetra\nAmino Acid Motif Properties on the Function of Protease-Activatable\nViral Vectors","volume":"2","author":"Robinson","year":"2016","journal-title":"ACS Biomater. Sci. Eng."},{"key":"2026081719275544500_cit121","doi-asserted-by":"publisher","first-page":"4740","DOI":"10.1021\/nn500550q","article-title":"Tunable Protease-Activatable Virus\nNanonodes","volume":"8","author":"Judd","year":"2014","journal-title":"ACS Nano"},{"key":"2026081719275544500_cit122","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.ymthe.2019.01.015","article-title":"Protease-Activatable Adeno-Associated\nVirus Vector for Gene Delivery\nto Damaged Heart Tissue","volume":"27","author":"Guenther","year":"2019","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit123","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1007\/s12195-014-0334-y","article-title":"Efficiency of Protease-Activatable\nVirus Nanonodes Tuned through Incorporation of Wild-Type Capsid Subunits","volume":"7","author":"Ho","year":"2014","journal-title":"Cell. Mol. Bioeng."},{"key":"2026081719275544500_cit124","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1016\/j.biomaterials.2012.01.027","article-title":"Simultaneous Gene Transduction and\nSilencing Using Stimuli-Responsive Viral\/Nonviral Chimeric Nanoparticles","volume":"33","author":"Cho","year":"2012","journal-title":"Biomaterials"},{"key":"2026081719275544500_cit125","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/gt.2011.84","article-title":"Elastin-Like Polypeptide Matrices\nfor Enhancing Adeno-Associated\nVirus-Mediated Gene Delivery to Human Neural Stem Cells","volume":"19","author":"Kim","year":"2012","journal-title":"Gene Ther."},{"key":"2026081719275544500_cit126","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1016\/S1525-0016(16)33480-3","article-title":"672. Hybrid\nAAV\/Phage Vector Enhances Chemotherapy\nEfficacy against Cancer","volume":"24","author":"Suwan","year":"2016","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit127","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1349-7006.1998.tb00482.x","article-title":"Adeno-Associated\nVirus Vector Containing the Herpes Simplex Virus Thymidine Kinase\nGene Causes Complete Regression of Intracerebrally Implanted Human\nGliomas in Mice, in Conjunction with Ganciclovir Administration","volume":"89","author":"Mizuno","year":"1998","journal-title":"Jpn. J. Cancer Res."},{"key":"2026081719275544500_cit128","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.nbt.2017.02.001","article-title":"Development\nof Efficient\nAdeno-Associated Virus (AAV)-Mediated Gene Delivery System with a\nPhytoactive Material for Targeting Human Melanoma Cells","volume":"37","author":"Lee","year":"2017","journal-title":"New Biotechnol."},{"key":"2026081719275544500_cit129","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.ejps.2012.02.022","article-title":"Conjugation\nof Paclitaxel\non Adeno-Associated Virus (AAV) Nanoparticles for Co-Delivery of Genes\nand Drugs","volume":"46","author":"Wei","year":"2012","journal-title":"Eur. J. Pharm. Sci."},{"key":"2026081719275544500_cit130","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1089\/hgtb.2015.040","article-title":"Stability and Compatibility of Recombinant\nAdeno-Associated Virus under Conditions Commonly Encountered in Human\nGene Therapy Trials","volume":"26","author":"Gruntman","year":"2015","journal-title":"Hum. Gene Ther: Methods."},{"key":"2026081719275544500_cit131","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/1566523054064968","article-title":"AAV Hybrid\nSerotypes:\nImproved Vectors for Gene Delivery","volume":"5","author":"Choi","year":"2005","journal-title":"Curr. Gene\nTher."},{"key":"2026081719275544500_cit132","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.coph.2015.08.002","article-title":"Engineering\nthe AAV Capsid to Optimize Vector\u2013Host-Interactions","volume":"24","author":"Bu\u0308ning","year":"2015","journal-title":"Curr. Opin. Pharmacol."},{"key":"2026081719275544500_cit133","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cobme.2018.09.004","article-title":"Adeno-Associated Virus\n(AAV) Vectors: Rational Design Strategies for Capsid Engineering","volume":"7","author":"Lee","year":"2018","journal-title":"Current Opinion in Biomedical Engineering."},{"key":"2026081719275544500_cit134","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s11095-007-9431-0","article-title":"Designer Gene Delivery\nVectors: Molecular\nEngineering and Evolution of Adeno-Associated Viral Vectors for Enhanced\nGene Transfer","volume":"25","author":"Kwon","year":"2008","journal-title":"Pharm. Res."},{"key":"2026081719275544500_cit135","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrg3742","article-title":"Engineering Adeno-Associated Viruses\nfor Clinical Gene Therapy","volume":"15","author":"Kotterman","year":"2014","journal-title":"Nat. Rev. Genet."},{"key":"2026081719275544500_cit136","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1038\/mt.2015.173","article-title":"E\nPluribus Unum:\n50 Years of Research, Millions of Viruses, and One Goal\ue5f8Tailored\nAcceleration of AAV Evolution","volume":"23","author":"Grimm","year":"2015","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit137","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ymthe.2006.05.009","article-title":"Adeno-Associated\nVirus Serotypes:\nVector Toolkit for Human Gene Therapy","volume":"14","author":"Wu","year":"2006","journal-title":"Mol.\nTher."},{"key":"2026081719275544500_cit138","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1128\/JVI.76.9.4559-4566.2002","article-title":"Adeno-Associated\nVirus Capsids Displaying Immunoglobulin-Binding\nDomains Permit Antibody-Mediated Vector Retargeting to Specific Cell\nSurface Receptors","volume":"76","author":"Ried","year":"2002","journal-title":"J. Virol."},{"key":"2026081719275544500_cit139","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/12491","article-title":"Genetic Capsid Modifications Allow\nEfficient Re-Targeting\nof Adeno-Associated Virus Type 2","volume":"5","author":"Girod","year":"1999","journal-title":"Nat. Med."},{"key":"2026081719275544500_cit140","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000055396","article-title":"Biology of HER2 and Its Importance\nin Breast Cancer","volume":"61","author":"Yarden","year":"2001","journal-title":"Oncology"},{"key":"2026081719275544500_cit141","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/j.1600-6143.2007.01772.x","article-title":"Adeno-Associated Viral\nVector-Mediated Interleukin-10 Prolongs Allograft Survival in a Rat\nKidney Transplantation Model","volume":"7","author":"Chen","year":"2007","journal-title":"Am. J. Transplant."},{"key":"2026081719275544500_cit142","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S1046-2023(02)00220-7","article-title":"Production and Purification\nof Serotype 1, 2, and 5 Recombinant Adeno-Associated Viral Vectors","volume":"28","author":"Zolotukhin","year":"2002","journal-title":"Methods"},{"key":"2026081719275544500_cit143","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1021\/bm200225x","article-title":"Reprogramming Virus Nanoparticles\nto Bind Metal Ions upon Activation with Heat","volume":"12","author":"Musick","year":"2011","journal-title":"Biomacromolecules"},{"key":"2026081719275544500_cit144","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1021\/acsnano.7b07804","article-title":"Reprogramming\nthe Activatable Peptide Display Function of Adeno-Associated\nVirus Nanoparticles","volume":"12","author":"Thadani","year":"2018","journal-title":"ACS Nano"},{"key":"2026081719275544500_cit145","doi-asserted-by":"publisher","first-page":"107453","DOI":"10.1016\/j.pharmthera.2019.107453","article-title":"Adeno-Associated Viral\nVector-Mediated Immune Responses: Understanding Barriers to Gene Delivery","volume":"207","author":"Nidetz","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"2026081719275544500_cit146","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.omtm.2019.11.014","article-title":"Cross-Packaging\nand Capsid Mosaic Formation in Multiplexed AAV Libraries","volume":"17","author":"Schmit","year":"2020","journal-title":"Mol. Ther.--Methods Clin. Dev."},{"key":"2026081719275544500_cit147","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/mt.2015.3","article-title":"High Capsid-Genome\nCorrelation Facilitates Creation of AAV Libraries for Directed Evolution","volume":"23","author":"Nonnenmacher","year":"2015","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit148","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1002\/bit.20562","article-title":"PEG Conjugation\nModerately Protects Adeno-Associated Viral Vectors against Antibody\nNeutralization","volume":"92","author":"Lee","year":"2005","journal-title":"Biotechnol. Bioeng."},{"key":"2026081719275544500_cit149","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/mt.2008.129","article-title":"Site-Specific\nModification of AAV Vector Particles with Biophysical Probes and Targeting\nLigands Using Biotin Ligase","volume":"16","author":"Stachler","year":"2008","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit150","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jconrel.2005.07.019","article-title":"Utility\nof PEGylated Recombinant Adeno-Associated Viruses for Gene Transfer","volume":"108","author":"Le","year":"2005","journal-title":"J. Controlled Release"},{"key":"2026081719275544500_cit151","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1006\/mthe.2001.0636","article-title":"Improved Method\nof Recombinant AAV2 Delivery for Systemic Targeted Gene Therapy","volume":"6","author":"Mah","year":"2002","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit152","doi-asserted-by":"publisher","first-page":"169","DOI":"10.2147\/IJN.S1608","article-title":"Magnetic Nanoparticles\nfor Gene and Drug Delivery","volume":"3","author":"McBain","year":"2008","journal-title":"Int. J. Nanomed."},{"key":"2026081719275544500_cit153","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.eurpolymj.2014.11.024","article-title":"Biomedical\nApplications of Hydrogels:\nA Review of Patents and Commercial Products","volume":"65","author":"Calo\u0301","year":"2015","journal-title":"Eur. Polym. J."},{"key":"2026081719275544500_cit154","doi-asserted-by":"publisher","first-page":"1906508","DOI":"10.1002\/adma.201906508","article-title":"Thermosensitive\nHydrogel Based on PEO\u2013PPO\u2013PEO\nPoloxamers for a Controlled in Situ Release of Recombinant\nAdeno-Associated Viral Vectors for Effective Gene Therapy of Cartilage\nDefects","volume":"32","author":"Madry","year":"2020","journal-title":"Adv. Mater."},{"key":"2026081719275544500_cit155","doi-asserted-by":"publisher","first-page":"20600","DOI":"10.1021\/acsami.6b06509","article-title":"PEO-PPO-PEO\nCarriers for RAAV-Mediated Transduction of Human Articular Chondrocytes in Vitro and in a Human Osteochondral Defect Model","volume":"8","author":"Rey-Rico","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"2026081719275544500_cit156","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1021\/acs.molpharmaceut.8b00331","article-title":"Effective\nRemodelling of Human Osteoarthritic\nCartilage by Sox9 Gene Transfer and Overexpression upon Delivery of\nRAAV Vectors in Polymeric Micelles","volume":"15","author":"Rey-Rico","year":"2018","journal-title":"Mol. Pharmaceutics"},{"key":"2026081719275544500_cit157","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1128\/MCB.14.4.2411","article-title":"Efficient and Sustained Gene Expression\nin Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated\nby Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes","volume":"14","author":"Philip","year":"1994","journal-title":"Mol. Cell. Biol."},{"key":"2026081719275544500_cit158","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1089\/hum.1996.7.11-1309","article-title":"Expression\nof the Human Multidrug Resistance and Glucocerebrosidase CDNAs from\nAdeno-Associated Vectors: Efficient Promoter Activity of AAV Sequences\nand in Vivo Delivery via Liposomes","volume":"7","author":"Baudard","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"2026081719275544500_cit159","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1359-0294(00)00090-X","article-title":"Liposome Application: Problems and Prospects","volume":"6","author":"Barenholz","year":"2001","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"2026081719275544500_cit160","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jconrel.2016.09.016","article-title":"Good Things\nCome in Small Packages: Overcoming Challenges to Harness Extracellular\nVesicles for Therapeutic Delivery","volume":"241","author":"Ingato","year":"2016","journal-title":"J. Controlled\nRelease"},{"key":"2026081719275544500_cit161","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ymeth.2019.11.007","article-title":"Extracellular Blebs: Artificially-Induced\nExtracellular Vesicles for Facile Production and Clinical Translation","volume":"177","author":"Thone","year":"2020","journal-title":"Methods"},{"key":"2026081719275544500_cit162","doi-asserted-by":"publisher","first-page":"9568","DOI":"10.1021\/acsnano.8b05377","article-title":"Cancer Cell-Derived, Drug-Loaded Nanovesicles Induced\nby Sulfhydryl-Blocking for Effective and Safe Cancer Therapy","volume":"12","author":"Ingato","year":"2018","journal-title":"ACS Nano"},{"key":"2026081719275544500_cit163","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.virol.2015.03.044","article-title":"Escape of Non-Enveloped Virus from\nIntact Cells","volume":"479","author":"Bird","year":"2015","journal-title":"Virology"},{"key":"2026081719275544500_cit164","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.mib.2016.05.004","article-title":"Extracellular Vesicles Are the Trojan\nHorses of Viral\nInfection","volume":"32","author":"Altan-Bonnet","year":"2016","journal-title":"Curr. Opin. Microbiol."},{"key":"2026081719275544500_cit165","doi-asserted-by":"publisher","first-page":"45329","DOI":"10.1038\/srep45329","article-title":"Exosome-Associated AAV2 Vector Mediates\nRobust Gene Delivery into the Murine Retina upon Intravitreal Injection","volume":"7","author":"Wassmer","year":"2017","journal-title":"Sci. Rep."},{"key":"2026081719275544500_cit166","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/bloodadvances.2017010181","article-title":"Enhanced Liver\nGene Transfer and Evasion of Preexisting Humoral Immunity with Exosome-Enveloped\nAAV Vectors","volume":"1","author":"Meliani","year":"2017","journal-title":"Blood Adv."},{"key":"2026081719275544500_cit167","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ymthe.2016.12.010","article-title":"Rescue of Hearing by Gene Delivery\nto Inner-Ear Hair Cells Using Exosome-Associated AAV","volume":"25","author":"Gyo\u0308rgy","year":"2017","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit168","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.omtm.2018.03.008","article-title":"Enhanced Production of Exosome-Associated\nAAV by Overexpression of the Tetraspanin CD9","volume":"9","author":"Schiller","year":"2018","journal-title":"Mol. Ther.--Methods Clin. Dev."},{"key":"2026081719275544500_cit169","doi-asserted-by":"publisher","first-page":"S106","DOI":"10.1016\/S1525-0016(16)33875-8","article-title":"266. G-Force Loading\nof Virus Vectors into Vesicles for Enhanced Gene Therapy Vehicles","volume":"23","author":"Fitzpatrick","year":"2015","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit170","doi-asserted-by":"publisher","first-page":"14325","DOI":"10.1074\/jbc.R117.799056","article-title":"Dysregulation\nof BCL-2 Family Proteins by Leukemia Fusion Genes","volume":"292","author":"Brown","year":"2017","journal-title":"J. Biol. Chem."},{"key":"2026081719275544500_cit171","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1128\/MCB.21.3.854-864.2001","article-title":"Downregulation of Bim, a Proapoptotic\nRelative of Bcl-2, Is a Pivotal Step in Cytokine-Initiated Survival\nSignaling in Murine Hematopoietic Progenitors","volume":"21","author":"Shinjyo","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"2026081719275544500_cit172","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10439-014-1104-7","article-title":"A Perspective on the Clinical Translation of Scaffolds\nfor Tissue Engineering","volume":"43","author":"Webber","year":"2015","journal-title":"Ann. Biomed. Eng."},{"key":"2026081719275544500_cit173","doi-asserted-by":"publisher","first-page":"191ra83","DOI":"10.1126\/scitranslmed.3005576","article-title":"Surface-Mediated\nBone Tissue Morphogenesis from Tunable Nanolayered Implant Coatings","volume":"5","author":"Shah","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2026081719275544500_cit174","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1073\/pnas.0908531107","article-title":"Active Multilayered\nCapsules for in Vivo Bone Formation","volume":"107","author":"Facca","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"2026081719275544500_cit175","doi-asserted-by":"publisher","first-page":"7543","DOI":"10.1016\/j.biomaterials.2011.06.062","article-title":"The Performance of\nBMP-2 Loaded TCP\/HAP\nPorous Ceramics with a Polyelectrolyte Multilayer Film Coating","volume":"32","author":"Crouzier","year":"2011","journal-title":"Biomaterials"},{"key":"2026081719275544500_cit176","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.omtm.2017.08.008","article-title":"One-Step Fabrication\nof Bone Morphogenetic\nProtein-2 Gene-Activated Porous Poly-L-Lactide Scaffold for Bone Induction","volume":"7","author":"Xue","year":"2017","journal-title":"Mol. Ther.--Methods Clin. Dev."},{"key":"2026081719275544500_cit177","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0939-6411(99)00029-6","article-title":"Prolonged Circulation Time of Doxorubicin-Loaded\nLiposomes Coated with a Modified Polyvinyl Alcohol After Intravenous\nInjection in Rats","volume":"48","author":"Takeuchi","year":"1999","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"2026081719275544500_cit178","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2165\/00002018-200124120-00004","article-title":"A Comparison\nof Liposomal Formulations of Doxorubicin with Drug Administered in\nFree Form: Changing Toxicity Profiles","volume":"24","author":"Waterhouse","year":"2001","journal-title":"Drug\nSaf."},{"key":"2026081719275544500_cit179","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jconrel.2006.08.017","article-title":"Accelerated\nBlood Clearance of PEGylated Liposomes upon Repeated Injections: Effect\nof Doxorubicin-Encapsulation and High-Dose First Injection","volume":"115","author":"Ishida","year":"2006","journal-title":"J. Controlled Release"},{"key":"2026081719275544500_cit180","doi-asserted-by":"publisher","DOI":"10.1002\/wnan.1488","article-title":"Extracellular Vesicles:\nNature\u2019s\nNanoparticles for Improving Gene Transfer with Adeno-Associated Virus\nVectors","volume":"10","author":"Gyo\u0308rgy","year":"2018","journal-title":"Wiley Interdisciplinary Reviews: Nanomedicine\nand Nanobiotechnology."},{"key":"2026081719275544500_cit181","first-page":"25","article-title":"Design and Construction\nof Functional AAV Vectors","volume-title":"Adeno-Associated\nVirus: Methods and Protocols","author":"Gray","year":"2011"},{"key":"2026081719275544500_cit182","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.omtm.2017.12.004","article-title":"Universal\nMethod for the Purification of Recombinant AAV Vectors of Differing\nSerotypes","volume":"9","author":"Nass","year":"2018","journal-title":"Mol. Ther.--Methods Clin. Dev."},{"key":"2026081719275544500_cit183","doi-asserted-by":"publisher","first-page":"14034","DOI":"10.1038\/mtm.2014.34","article-title":"A Simplified\nPurification Protocol for Recombinant Adeno-Associated Virus Vectors","volume":"1","author":"Potter","year":"2014","journal-title":"Mol. Ther.--Methods Clin. Dev."},{"key":"2026081719275544500_cit184","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.omtm.2018.10.015","article-title":"Highly Efficient Ultracentrifugation-Free Chromatographic\nPurification of Recombinant AAV Serotype 9","volume":"11","author":"Tomono","year":"2018","journal-title":"Mol. Ther.--Methods Clin. Dev."},{"key":"2026081719275544500_cit185","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1016\/S1525-0016(16)32906-9","article-title":"97. Large Scale\nPurification of AAV with Continuous Flow Ultracentrifugation","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"2026081719275544500_cit186","unstructured":"Content and Review of Chemistry, Manufacturing,\nand Control (CMC)\nInformation for Human Somatic Cell Therapy Investigational New Drug\nApplications (INDs). Guidance for FDA Reviewers\nand Sponsors; FDA: Silver Spring, MD, 2008."}],"container-title":["ACS Nano"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsnano.0c03850","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/ancac3\/article-pdf\/14\/11\/14262\/8362429\/nn0c03850.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/ancac3\/article-pdf\/14\/11\/14262\/8362429\/nn0c03850.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:16:07Z","timestamp":1787040967000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/ancac3\/article\/14\/11\/14262\/809026\/Synthetically-Engineered-Adeno-Associated-Virus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":186,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2020,10,19]]},"published-print":{"date-parts":[[2020,11,24]]}},"URL":"https:\/\/doi.org\/10.1021\/acsnano.0c03850","relation":{},"ISSN":["1936-0851","1936-086X"],"issn-type":[{"value":"1936-0851","type":"print"},{"value":"1936-086X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]}}}